Home › Companies › VERVE THERAPEUTICS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and VERVE THERAPEUTICS INC.’s Form 8-K, filed June 10, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 5, 2025: 5 items on VERVE THERAPEUTICS INC.’s Form 8-K, filed June 10, 2025: 2 approved · 3 passed (calculated).
Notable dissent: 1 director (15.5% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025
Explore VERVE THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are VERVE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Lonnel Coats | 58,699,561 | -- | -- | 686,894 | 13,681,266 | 99% | Passed (calculated) | — |
| Elect Director: Jodie Morrison | 58,628,402 | -- | -- | 758,053 | 13,681,266 | 99% | Passed (calculated) | — |
| Elect Director: Krishna Yeshwant, M.D. | 50,208,438 | -- | -- | 9,178,017 | 13,681,266 | 85% | Passed (calculated) | — |
| 2. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm | 72,754,346 | 75,512 | 237,863 | -- | 0 | 99.9% | Approved | — |
| 3. Approval, on an Advisory Basis, of Compensation Paid to Company's Named Executive Officers | 56,159,136 | 2,748,937 | 478,381 | -- | 13,681,266 | 95% | Approved | — |
Source: VERVE THERAPEUTICS INC., Form 8-K, filed with the SEC on June 10, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
197 asset managers disclosed a vote on at least one VERVE THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Election of three Class I directors to our board of directors, each to serve until the 2028 annual meeting of stockholders: Jodie Morrison
VERVE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jodie Morrison”): 58,628,402 for, 758,053 withheld, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 14,093,115 for, 241,078 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,862,068 | 0 | 0 | 0 | For |
| BlackRock | 3,493,992 | 0 | 0 | 0 | For |
| Fidelity | 1,421,709 | 0 | 0 | 0 | For |
| TIAA | 1,220,428 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,180,297 | 0 | 0 | 0 | For |
| State Street | 655,489 | 0 | 0 | 0 | For |
| Charles Schwab | 571,361 | 0 | 0 | 0 | For |
| Goldman Sachs | 221,032 | 0 | 0 | 0 | For |
| Equitable | 125,169 | 0 | 0 | 67,300 | Mixed |
| American Century | 160,000 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 146,507 | Withhold |
| Global X | 118,874 | 0 | 0 | 0 | For |
| SEI | 111,740 | 0 | 0 | 0 | For |
| Nationwide | 93,625 | 0 | 0 | 0 | For |
| Lincoln Financial | 86,632 | 0 | 0 | 1,676 | For |
| QUANTITATIVE MASTER SERIES LLC | 87,383 | 0 | 0 | 0 | For |
| Northwestern Mutual | 82,809 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 65,164 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 48,022 | 0 | 0 | 0 | For |
| John Hancock | 43,529 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 43,283 | 0 | 0 | 0 | For |
| ProShares | 37,893 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 36,757 | 0 | 0 | 0 | For |
| Pacific Life | 36,026 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 34,803 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: Election of three Class I directors to our board of directors, each to serve until the 2028 annual meeting of stockholders: Krishna Yeshwant, M.D.
VERVE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Krishna Yeshwant, M.D.”): 50,208,438 for, 9,178,017 withheld, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 9,951,675 for, 4,382,518 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,862,068 | 0 | 0 | 0 | For |
| BlackRock | 471,284 | 0 | 0 | 3,022,708 | Mixed |
| Fidelity | 1,394,472 | 0 | 0 | 27,237 | For |
| TIAA | 1,220,428 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,180,297 | 0 | 0 | 0 | For |
| State Street | 654,838 | 0 | 0 | 651 | For |
| Charles Schwab | 571,361 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 221,032 | Withhold |
| Equitable | 0 | 0 | 0 | 192,469 | Withhold |
| American Century | 0 | 0 | 0 | 160,000 | Withhold |
| Dimensional | 0 | 0 | 0 | 146,507 | Withhold |
| Global X | 118,874 | 0 | 0 | 0 | For |
| SEI | 111,740 | 0 | 0 | 0 | For |
| Nationwide | 3,809 | 0 | 0 | 89,816 | Withhold |
| Lincoln Financial | 52,700 | 0 | 0 | 35,608 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 87,383 | Withhold |
| Northwestern Mutual | 82,809 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 65,164 | Withhold |
| SEI Exchange Traded Funds | 48,022 | 0 | 0 | 0 | For |
| John Hancock | 17,499 | 0 | 0 | 26,030 | Mixed |
| Columbia Threadneedle | 43,283 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 37,893 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 36,757 | 0 | 0 | 0 | For |
| Pacific Life | 0 | 0 | 0 | 36,026 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 34,803 | Withhold |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Election of three Class I directors to our board of directors, each to serve until the 2028 annual meeting of stockholders: Lonnel Coats
VERVE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Lonnel Coats”): 58,699,561 for, 686,894 withheld, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 14,093,633 for, 240,560 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,862,068 | 0 | 0 | 0 | For |
| BlackRock | 3,493,992 | 0 | 0 | 0 | For |
| Fidelity | 1,421,709 | 0 | 0 | 0 | For |
| TIAA | 1,220,428 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,180,297 | 0 | 0 | 0 | For |
| State Street | 655,489 | 0 | 0 | 0 | For |
| Charles Schwab | 571,361 | 0 | 0 | 0 | For |
| Goldman Sachs | 221,032 | 0 | 0 | 0 | For |
| Equitable | 125,169 | 0 | 0 | 67,300 | Mixed |
| American Century | 160,000 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 146,507 | Withhold |
| Global X | 118,874 | 0 | 0 | 0 | For |
| SEI | 111,740 | 0 | 0 | 0 | For |
| Nationwide | 93,625 | 0 | 0 | 0 | For |
| Lincoln Financial | 86,632 | 0 | 0 | 1,676 | For |
| QUANTITATIVE MASTER SERIES LLC | 87,383 | 0 | 0 | 0 | For |
| Northwestern Mutual | 82,809 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 65,164 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 48,022 | 0 | 0 | 0 | For |
| John Hancock | 43,529 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 43,283 | 0 | 0 | 0 | For |
| ProShares | 37,893 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 36,757 | 0 | 0 | 0 | For |
| Pacific Life | 36,026 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 34,803 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
95% Approved · of votes cast
Prior year: 87.8% for (June 6, 2024 meeting) ▲ 7.5 pts
Description as filed by funds: APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.
VERVE THERAPEUTICS INC.’s own tally for this item (“3. Approval, on an Advisory Basis, of Compensation Paid to Company's Named Executive Officers”): 56,159,136 for, 2,748,937 against — passed, per its Form 8-K filed June 10, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Approval, on an Advisory Basis, of Compensation Paid to Company's Named Executive Officers The stockholders of the Company approved, on an advisory basis, the compensation paid to its named executive officers.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of VERVE THERAPEUTICS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Say on pay” (2 managers, 200 against).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,862,068 | 0 | 0 | 0 | For |
| BlackRock | 3,493,992 | 0 | 0 | 0 | For |
| Fidelity | 1,421,709 | 0 | 0 | 0 | For |
| TIAA | 1,220,428 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,180,297 | 0 | 0 | 0 | For |
| State Street | 655,340 | 149 | 0 | 0 | For |
| Charles Schwab | 571,361 | 0 | 0 | 0 | For |
| Goldman Sachs | 221,032 | 0 | 0 | 0 | For |
| Equitable | 192,469 | 0 | 0 | 0 | For |
| American Century | 0 | 160,000 | 0 | 0 | Against |
| Dimensional | 0 | 146,507 | 0 | 0 | Against |
| Global X | 0 | 118,874 | 0 | 0 | Against |
| SEI | 0 | 111,740 | 0 | 0 | Against |
| Nationwide | 89,816 | 3,809 | 0 | 0 | For |
| Lincoln Financial | 86,632 | 1,676 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 87,383 | 0 | 0 | 0 | For |
| Northwestern Mutual | 82,809 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 65,164 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 0 | 48,022 | 0 | 0 | Against |
| John Hancock | 43,529 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 43,283 | 0 | 0 | 0 | For |
| ProShares | 37,893 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 36,757 | 0 | 0 | 0 | For |
| Pacific Life | 36,026 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 34,803 | 0 | 0 | 0 | For |
Fund voting reports, all 53 managers: 13,700,528 for, 621,824 against, 11,841 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| GV Management Company, L.L.C. | 12,168,489 | 0 | 0 | 0 | For |
| BVF INC/IL | 6,904,050 | 0 | 0 | 0 | For |
| Novo Holdings A/S | 3,170,000 | 0 | 0 | 0 | For |
| Woodline Partners LP | 2,755,088 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,426,775 | 0 | 0 | 0 | For |
| BlackRock | 2,202,077 | 18,318 | 0 | 0 | For |
| State Street | 2,053,775 | 387 | 0 | 0 | For |
| ARCH Venture Management, LLC | 2,008,923 | 0 | 0 | 0 | For |
| Casdin Capital, LLC | 1,738,237 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,490,175 | 0 | 0 | 0 | For |
| Nuveen | 1,250,709 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 0 | 764,793 | 0 | 0 | Against |
| Charles Schwab | 571,361 | 0 | 0 | 0 | For |
| Palo Alto Investors LP | 0 | 0 | 0 | 0 | -- |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 440,466 | 0 | 0 | 0 | For |
| Northern Trust | 437,245 | 0 | 0 | 0 | For |
| Point72 | 424,345 | 0 | 0 | 0 | For |
| Two Sigma | 306,660 | 0 | 0 | 0 | For |
| JPMorgan | 298,551 | 0 | 0 | 0 | For |
| Fidelity | 278,131 | 0 | 0 | 0 | For |
| Impresa Management LLC | 247,153 | 0 | 0 | 0 | For |
| Citadel | 222,941 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 0 | 179,545 | 0 | 0 | Against |
| Wellington | 0 | 177,621 | 0 | 0 | Against |
| STIFEL NICOLAUS & CO INC \MO\ | 164,813 | 0 | 0 | 0 | For |
Institutional-manager reports, all 156 managers: 42,774,920 for, 2,201,097 against, 2,139 abstained, 560,534 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 99.9% for (June 6, 2024 meeting) unchanged
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025
VERVE THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm”): 72,754,346 for, 75,512 against — passed, per its Form 8-K filed June 10, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 14,322,352 for, 11,841 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,862,068 | 0 | 0 | 0 | For |
| BlackRock | 3,493,992 | 0 | 0 | 0 | For |
| Fidelity | 1,421,709 | 0 | 0 | 0 | For |
| TIAA | 1,220,428 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,180,297 | 0 | 0 | 0 | For |
| State Street | 655,489 | 0 | 0 | 0 | For |
| Charles Schwab | 571,361 | 0 | 0 | 0 | For |
| Goldman Sachs | 221,032 | 0 | 0 | 0 | For |
| Equitable | 192,469 | 0 | 0 | 0 | For |
| American Century | 160,000 | 0 | 0 | 0 | For |
| Dimensional | 146,507 | 0 | 0 | 0 | For |
| Global X | 118,874 | 0 | 0 | 0 | For |
| SEI | 111,740 | 0 | 0 | 0 | For |
| Nationwide | 93,625 | 0 | 0 | 0 | For |
| Lincoln Financial | 88,308 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 87,383 | 0 | 0 | 0 | For |
| Northwestern Mutual | 82,809 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 65,164 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 48,022 | 0 | 0 | 0 | For |
| John Hancock | 43,529 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 43,283 | 0 | 0 | 0 | For |
| ProShares | 37,893 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 36,757 | 0 | 0 | 0 | For |
| Pacific Life | 36,026 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 34,803 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported.
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | Vanguard | 3,862,068 |
| 2 | BlackRock | 3,493,992 |
| 3 | Fidelity | 1,421,709 |
| 4 | TIAA | 1,220,428 |
| 5 | T. Rowe Price | 1,180,297 |
| 6 | State Street | 655,489 |
| 7 | Charles Schwab | 571,361 |
| 8 | Goldman Sachs | 221,032 |
| 9 | Equitable | 192,469 |
| 10 | American Century | 160,000 |
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | GV Management Company, L.L.C. | 12,168,489 |
| 2 | BVF INC/IL | 6,904,050 |
| 3 | Novo Holdings A/S | 3,170,000 |
| 4 | Woodline Partners LP | 2,755,088 |
| 5 | T. Rowe Price | 2,426,775 |
| 6 | BlackRock | 2,220,395 |
| 7 | State Street | 2,054,162 |
| 8 | ARCH Venture Management, LLC | 2,008,923 |
| 9 | Casdin Capital, LLC | 1,738,237 |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1,490,175 |
Shown as share counts, not percentages: no shares-outstanding figure has been matched to VERVE THERAPEUTICS INC. for the 2024-2025 season, so there is no denominator to divide by.
At VERVE THERAPEUTICS INC.'s shareholder meeting held June 5, 2025, in the 2024-2025 proxy season, 197 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 997 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS. — VERVE THERAPEUTICS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: VERVE THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
VERVE THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page).
Proxy Votes Now, “VERVE THERAPEUTICS INC. 2025 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/verve-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.